Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

HISTORICAL FACTS: Looking into fulcrum therapeutics s return on capital employed - The Untold Story

Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q1 sales of $2.59 million. Earnings fell to a loss of $25.93 million, resulting in a 10.41% decrease from last quarter. Fulcrum Therapeutics collected $5.06 million in revenue during Q4, but reported earnings showed a $23.48 million loss.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.